TABLE 3.
The diagnostic value of 12 TAAbs for identifying BC from breast benign disease (BD)
| TAAb | Cut‐off (ng/mL) | Positive(%) | χ2 | P | Se (%) | Sp (%) | YI | Accuracy (%) | FPR (%) | FNR (%) | PPV (%) | NPV (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BC | BD | ||||||||||||
| (n = 399) | (n = 200) | ||||||||||||
| ALK | 26 911 | 94 (23.6) | 38 (19.0) | 1.612 | .204 | 23.6 | 82.0 | 0.1 | 22.0 | 18.0 | 76.4 | 71.2 | 51.8 |
| BRCA2 | 22 292 | 118 (29.6) | 13 (6.5) | 41.51 | <.001 | 29.6 | 93.5 | 0.2 | 21.9 | 6.5 | 70.4 | 82.0 | 57.0 |
| CDKN2A | 24 963 | 100 (25.1) | 34 (17.0) | 4.987 | .026 | 25.1 | 83.0 | 0.1 | 22.4 | 17.0 | 74.9 | 59.6 | 52.6 |
| CEBPA | 23 449 | 147 (36.8) | 22 (11.0) | 43.927 | <.001 | 36.8 | 89.0 | 0.3 | 28.2 | 11.0 | 63.2 | 77.0 | 58.5 |
| CEP55 | 43 553 | 91 (22.8) | 26 (13.0) | 8.152 | .004 | 22.8 | 87.0 | 0.1 | 19.5 | 13.0 | 77.2 | 63.7 | 53.0 |
| FUBP1 | 19 421 | 102 (25.6) | 32 (16.0) | 7.017 | .008 | 25.6 | 84.0 | 0.1 | 22.4 | 16.0 | 74.4 | 61.5 | 53.0 |
| GATA3 | 19 858 | 196 (49.1) | 36 (18.0) | 54.379 | <.001 | 49.1 | 82.0 | 0.3 | 38.7 | 18.0 | 50.9 | 73.2 | 61.7 |
| HIST1H3B | 35 877 | 83 (20.8) | 36 (18.0) | 0.657 | .418 | 20.8 | 82.0 | 0.0 | 19.9 | 18.0 | 79.2 | 53.6 | 50.9 |
| HRAS | 32 356 | 127 (31.8) | 26 (13.0) | 24.836 | <.001 | 31.8 | 87.0 | 0.2 | 25.5 | 13.0 | 68.2 | 71.0 | 56.1 |
| IMP2/p62 | 35 344 | 133 (33.3) | 42 (21.0) | 9.799 | .002 | 33.3 | 79.0 | 0.1 | 29.2 | 21.0 | 66.7 | 61.3 | 54.2 |
| PTCH1 | 34 216 | 177 (44.4) | 54 (27.0) | 16.948 | <.001 | 44.4 | 73.0 | 0.2 | 38.7 | 27.0 | 55.6 | 62.2 | 56.8 |
| RalA | 49 331 | 117 (29.3) | 32 (16.0) | 12.655 | <.001 | 29.3 | 84.0 | 0.1 | 24.9 | 16.0 | 70.7 | 64.7 | 54.3 |
The cut‐off value was considered as the maximum Youden index at the point of more than 90% specificity
FNR, false‐negative rate; FPR, false‐positive rate; NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity; YI, Youden index.